Amarin Corp Plcuk (AMRN) Other Non-Current Liabilities (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Other Non-Current Liabilities of $11.3 million for Q2 2026, down 5.21% year-over-year from $11.9 million in Q2 2025, and up 1.57% quarter-over-quarter from $11.1 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Other Non-Current Liabilities for 17 consecutive years, with $11.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Liabilities fell 5.21% year-over-year to $11.3 million; the TTM figure through Jun 2026 stood at $11.3 million (down 5.21% YoY), while the FY2025 annual figure was $11.0 million, down 4.75% from the prior year.
- Other Non-Current Liabilities grew to $11.3 million in Q2 2026 per AMRN's latest filing, from $11.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $12.0 million in Q3 2025 and bottomed at $7.2 million in Q2 2023.
- Historically, Other Non-Current Liabilities has averaged $9.6 million across 5 years, with a median of $9.4 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 81.25% — and 2023, when it slipped 25.0%.
- Amarin Corp Plc\Uk's Other Non-Current Liabilities stood at $8.2 million in 2022, then grew by 10.47% to $9.1 million in 2023, then grew by 26.89% to $11.5 million in 2024, then fell by 4.75% to $11.0 million in 2025, then gained by 3.12% to $11.3 million in 2026.
- Business Quant data shows AMRN's Other Non-Current Liabilities at $11.3 million in Q2 2026, $11.1 million in Q1 2026, and $11.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.30 Mn |
| Mar 31, 2026 | 11.12 Mn |
| Dec 31, 2025 | 10.96 Mn |
| Sep 30, 2025 | 11.96 Mn |
| Jun 30, 2025 | 11.92 Mn |
| Mar 31, 2025 | 11.64 Mn |
| Dec 31, 2024 | 11.50 Mn |
| Sep 30, 2024 | 9.47 Mn |
| Jun 30, 2024 | 9.34 Mn |
| Mar 31, 2024 | 9.20 Mn |
| Dec 31, 2023 | 9.06 Mn |
| Sep 30, 2023 | 7.27 Mn |
| Jun 30, 2023 | 7.16 Mn |
| Mar 31, 2023 | 8.61 Mn |
| Dec 31, 2022 | 8.21 Mn |
| Sep 30, 2022 | 9.70 Mn |
| Jun 30, 2022 | 7.64 Mn |
| Mar 31, 2022 | 7.49 Mn |
| Dec 31, 2021 | 7.65 Mn |
| Sep 30, 2021 | 5.35 Mn |